PuMP: Oncolytic HSV1 MVR-C5252 in Patients with rHGG (Recurrent Glioma) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.

¿Cuál es la Condición que se está estudiando?

Malignant Glioma

¿Quién puede participar en el Estudio?

Adults ages 18+ who are diagnosed with recurrent high-grade glioma.

For more information about this study, please call 919-684-5301.

Grupo etario

Adultos

¿Qué Implica?

If you join the study, you will:

Have a physical and neurological exam and other tests
Have magnetic resonance imaging (MRI) of the brain
Realizar extracciones de sangre
Have brain tumor biopsy and testing of tumor sample
Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head
Get the study drug infused through an external pump and the implanted catheter

Detalles del Estudio

Título Completo

The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma

Investigador Principal